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Abstract
Background: A major challenge in the application of marrow transplantation as a route to
immunological tolerance of a transplanted organ is to achieve hematopoietic stem cell (HSC)
engraftment with minimal myelosuppressive treatments.
Results:  We here describe a combined antibody protocol which can achieve long-term
engraftment with clinically relevant doses of MHC-mismatched bone marrow, without the need for
myelosuppressive drugs. Although not universally applicable in all strains, we achieved reliable
engraftment in permissive strains with a two-stage strategy: involving first, treatment with anti-CD8
and anti-CD4 in advance of transplantation; and second, treatment with antibodies targeting CD4,
CD8 and CD40L (CD154) at the time of marrow transplantation. Long-term mixed chimerism
through co-receptor and co-stimulation blockade facilitated tolerance to donor-type skin grafts,
without any evidence of donor-antigen driven regulatory T cells.
Conclusion: We conclude that antibodies targeting co-receptor and co-stimulatory molecules
synergise to enable mixed hematopoietic chimerism and central tolerance, showing that neither
cytoreductive conditioning nor 'megadoses' of donor bone marrow are required for donor HSC
to engraft in permissive strains.
Background
Bone marrow transplantation (BMT) has widespread ther-
apeutic potential in the treatment of hematological malig-
nancies, genetic defects in the hematopoietic system and
autoimmunity [1-4]. The goal of achieving solid organ
transplantation tolerance may also be facilitated by the
induction of mixed hematopoietic chimerism following
the transplantation of donor bone marrow (BM) [5]. It
has been a long held assumption that the engraftment of
bone marrow transplants requires the creation of "space"
in the host. "Space" has usually been created using myelo-
ablative conditioning regimens that include gamma irra-
diation or cytotoxic agents, both associated with
undesirable side effects. As a consequence, there have
been efforts to minimize the myeloablative conditioning
by developing protocols where engraftment is facilitated
with the combination of monoclonal antibodies (mAbs)
[6]. The intensity of myelosuppressive conditioning strat-
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egies, such as low-dose total body irradiation or busulfan,
is able to be reduced by the use of anti-CD40L mAbs ("co-
stimulation blockade") [7-9]. Large or "mega-doses" of
donor BM have also been shown to be helpful in promot-
ing engraftment [10]. "Mega-doses" of donor bone mar-
row and anti-CD40L mAbs in the presence [11,12] or
absence of donor specific transfusion [13,14], are suffi-
cient to ensure stable bone marrow engraftment in the
absence of myelosuppression. We now demonstrate that a
combination of mAbs (targeting CD4, CD8 and CD40L),
previously shown capable of inducing dominant trans-
plantation tolerance to allogeneic skin grafts [15], permits
the engraftment of donor marrow in some strain combi-
nations. This leads to long-term chimerism and transplan-
tation tolerance without the need for mega-doses of
donor bone marrow or myelosuppressive conditioning.
Results
Mixed chimerism and tolerance using a conventional dose 
of donor BM without the need for myelosuppression
To establish the minimum number of marrow cells
needed to achieve chimerism and tolerance, CBA mice
were treated with three doses of 1 mg of each of the block-
ing mAbs to CD4, CD8 and CD40 L on alternate days 4
weeks prior to BMT, transplanted with different numbers
of T cell-depleted B10 BM cells, and further treated with 1
mg of the same antibodies on day 0, 2 and 4 relative to
BMT (Figure 1A). Peripheral blood samples were collected
50 days (not shown) and 120 days following BMT, and
the level of chimerism was quantified by flow cytometry
(Figure 1B). Chimerism was found to be stable since the
levels detected at these two time points were always simi-
lar in any individual mouse. All animals transplanted
with 1×107, 2×107 or 4×107 T cell-depleted BM cells had
Induction of BM engraftment with CD4, CD8 and CD40L mAbs Figure 1
Induction of BM engraftment with CD4, CD8 and CD40L mAbs. (A) CBA mice were treated with three doses of 1 
mg of non-depleting CD4, CD8 and CD40L mAbs on days -28, -26, -24, 0, 2 and 4 in relation to the day of BMT (day 0). (B) 
The level of hematopoietic chimerism was determined among peripheral blood mononuclear cells of CBA mice, transplanted 
with different numbers of B10 BM, by flow cytometry. CBA mice not subjected to BMT were used as a control group. Results 
are from day 120 following BMT. Difference from the control group is statistically significant in animals transplanted with 1×107 
cells or more (p < 0.02). (C) The mice were transplanted with donor type (B10) skin grafts 50 days following BMT. Grafts sur-
vived indefinitely in animals where mixed chimerism had been established, being the difference between animals transplanted 
with 1×107 BM cells or more, and animals transplanted with 1×106 or 5×106 BM cells statistically significant (p < 0.02).
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The requirement for first-stage antibody treatmentin advance of BMT Figure 2
The requirement for first-stage antibody treatmentin advance of BMT. Except for control mice which received no 
treatment, all mice represented in this figure received CD4, CD8 and CD40L antibodies at the time of BMT (1 mg each ip on 
days 0, 2 and 4, relative to BMT on day 0). The first-stage antibody treatment was varied as described. CBA mice (A) and 
BALB/c mice (B) were transplanted with different doses of T cell depleted B10 BM, under the cover non-depleting CD4, CD8 
and CD40L mAbs. Only one group of mice from each strain received the mAb treatment 4 weeks prior to BMT. Hematopoi-
etic chimerism determined by flow cytometry 120 days following BMT is shown. In both strains the difference between 
untransplanted controls and animals not treated in advance of BMT is not statistically significant. Survival of B10 skin grafts, 
transplanted 50 days following BMT is represented. Only animals where mixed chimerism could be detected accepted the skin 
grafts indefinitely (p < 0.01 to any other group). (C) CBA mice were treated with 3 × 1 mg of CD4 and CD8 mAbs alone, or 
combined with the same dose of CD40L mAbs, 4 weeks before the transplantation of 4×107 T cell depleted B10 BM. One 
group was not treated at that time. Together with the BMT all animals were treated with CD4, CD8 and CD40L mAbs as 
described in Figure 1. Animals that did not receive BMT were used as negative controls. (D) Experiment identical to the one 
described in (C), using different combinations of mAb 4 weeks before BMT. No statistically significant difference was observed 
between the transplanted groups in the levels of hematopoietic chimerism 120 days following BMT.
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detectable levels of chimerism, as did one mouse trans-
planted with 5×106 BM cells. All mice transplanted with
1×106 BM cells demonstrated no detectable chimerism.
To determine whether tolerance was dependent on the
degree of chimerism, all mice were challenged with donor
type skin grafts on day 50 following BMT. In addition,
(BALB/c × B10)F1 skin was transplanted on day 120 to
determine whether any tolerance observed was dominant,
in which linked suppression [16] would be the expected
outcome. All animals that had detectable chimerism
accepted donor-type skin indefinitely (Figure 1C). (BALB/
c × B10)F1 skin grafts were readily rejected by all mice
(MST=13d) indicating that we could not elicit linked sup-
pression and dominant tolerance.
These data demonstrate, therefore, that 1×107  T cell-
depleted BM cells together with this particular antibody
protocol, is sufficient to achieve stable mixed chimerism,
and a non-dominant form of transplantation tolerance.
Remarkably, this is achieved in the absence of myeloabla-
tive or myelosuppressive conditioning.
Antibody first-stage treatment of the recipient is helpful in 
enabling bone marrow engraftment
We examined the requirements for a first-stage treatment
in overcoming the immunologic resistance to BM engraft-
ment. CBA or BALB/c mice were transplanted with differ-
ent doses of donor BM and treated with 3 × 1 mg of CD4,
CD8 and CD40L mAbs at the time of BMT, in the presence
or absence of antibody treatment 4 weeks in advance of
BMT. Only animals treated with the first-stage antibody-
treatment in advance of BMT had detectable chimerism
(Figure 2A and 2B). Mice transplanted with BM in the
absence of first-stage treatment, readily rejected donor
type skin grafts transplanted 50 days following BMT (Fig-
ure 2A and 2B).
The successful treatment regime used above was not, how-
ever, effective in B10 mice that had been transplanted
with 2×107 T cell-depleted BM from CBA donors. Chimer-
ism was less than 1% and all mice rejected donor-type
skin (not shown).
Although antibody-treatment was critical at the time of
BMT (as described below), first-stage treatment did not,
however, seem to be an absolute requirement in all exper-
iments. In one experiment, we observed that omission of
the CD40L mAb made no difference to the efficacy of the
first-stage treatment (Figure 2C), while in another we
actually achieved long term engraftment in the absence of
any first-stage treatment whatsoever (Figure 2D). Clearly,
there are variations between experiments in the need for
first-stage treatment, but more importantly, treatment
with CD4 and CD8 mAbs does seem to guarantee routine
success in permissive strains. It should be noted that CD8
mAbs on their own could not be tested for the first-stage
treatment because they lead to sensitization to rat anti-
bodies, nullifying the efficacy of subsequent antibody
administration [17]. This does not happen when CD8
antibodies are combined with CD4 or CD40L antibodies.
To investigate the impact of the first-stage treatment on T
cell populations, spleen cells from animals treated with
CD4 and CD8 mAbs were collected 4 weeks following
treatment (at the time donor BM is usually transplanted)
and analysed by flow cytometry. Antibody-treated mice
showed a marked reduction in CD8+ T cells (Table 1). Rel-
ative to untreated controls, antibody-treated mice had a
significantly higher frequency of CD44+ cells amongst
CD8+ cells. Small but significant changes within the CD4+
population were observed, including an increase of
CD44+ and CD25+ cells in antibody-treated mice.
Anti-CD40L mAb is a necessary component of the second 
stage treatment
We investigated whether a 2-stage protocol consisting
solely of co-receptor blockade with omission of co-stimu-
lation blockade would still enable the engraftment of
donor BM. All mice received the first-stage treatment con-
sisting of co-receptor blockade alone initiated 4 weeks
before transplantation. At the time of transfer of 2×107 T
cell-depleted B10 bone marrow cells, the mice were split
into three groups. One group received CD4, CD8 and
CD40L mAbs; a second received CD4 and CD8 mAbs and
a third received no mAbs. Chimerism was only achieved
in the group which received the triple cocktail at the time
of BM transplantation.
Bone marrow engraftment in congenic mouse strains
Based on the failure of the 2-stage protocol to enable
engraftment in B10 recipients of CBA bone marrow, we
turned to a congenic system to provide a less stringent
immunological barrier. In 2 experiments, no engraftment
was observed in B6 recipients of congenic B6.CD45.1
bone marrow in the absence of antibody-treatment, while
control CBA recipients which received the 2-stage proto-
col were chimeric (mean +/- SD = 6.4% +/- 1.5 and 4.3%
+/- 1.3). B6 recipients of the 2-stage antibody protocol
plus congenic B6.CD45.1 bone marrow showed low but
significant levels of chimerism (mean +/- SD = 2.7% +/-
0.3 and 2.7% +/-0.6) (Figure 4A).
We investigated whether BM engraftment in congenic
mice might be facilitated by targeting NK cells. The spe-
cific targeting of NK cells by treatment with anti-NK1.1
antibody five days prior to BMT did not, however, enable
BM engraftment (Figure 4B).BMC Immunology 2006, 7:9 http://www.biomedcentral.com/1471-2172/7/9
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Discussion
These new data show that a combination of antibodies
targeting the CD4 and CD8 T cell co-receptors plus the
CD40L molecule can facilitate bone marrow engraftment
in the absence of any myelosuppressive conditioning of
the recipient. A dose of marrow as low as 1×107 T cell-
depleted BM (approximately 4×108 cells/kg) could estab-
lish mixed chimerism detectable 120 days following BMT.
This state of mixed chimerism was sufficient to enable
long-term acceptance of donor type skin allografts.
Although the level of chimerism achieved was found to
vary between experiments, we confirmed by titrating the
dose of bone marrow, that even low levels of chimerism
are maintained long-term, and these are compatible with
long-term acceptance of skin grafts.
We have previously observed the resistance of B6 mice to
tolerance induction to skin grafts by our antibody proto-
cols [18]. In this study, the same was found for bone mar-
row transplants. A congenic system was employed to test
the effect of the full 2-stage protocol in a system where the
intensity of the allogeneic response is markedly reduced,
although some antigenicity of the CD45.1 allele has been
reported [19]. The levels of chimerism achieved in con-
genic B6 recipients were lower than fully allogeneic CBA
recipients (Figure 4A), showing a relative resistance of B6
recipients to engraftment of donor hematopoeitic stem
cells. The mechanism of resistance to engraftment is
unclear, but it may be that 'resident' B6 stem cells enjoy an
advantage in competing for 'niches', for instance by being
more abundant than in the other strains [20]. There are
several reports in which mixed chimerism was achieved in
B6 recipients by combining co-stimulation blockade with
either irradiation or 'megadoses' of bone marrow
[11,12,21]. Interestingly, targeting CD40L alone was suf-
ficient for chimerism in MHC-mismatched B10.BR recipi-
ents of B6 bone marrow [13], a donor-recipient
combination which shares 'minors'. Unlike B6 mice, it
seems B10.BR recipients (H-2k with 'black minors') do not
display resistance to donor stem cell engraftment, which
therefore might be associated with the H-2b haplotype of
the MHC.
We were surprised by the variability in the requirement for
the first-stage antibody-treatment in engraftment of donor
stem cells. This variability between experiments may be
explained by the combined treatment being capable of
minimizing some component of heterologous immunity;
that is, a heightened state of alloreactivity as a result of
exposure to environmental antigens [22], which could
vary between groups of experimental mice. The partial
depletion of CD8+ cells by the first-stage treatment (Table
1) was also unexpected because the isotype of the CD8
antibody used is rat IgG2a, which is the same isotype as
the patently non-depleting CD4 antibody used. We have
observed this same CD8 antibody to be non-depleting in
previous studies [23]. This 'blocking' CD8 antibody may
hinder TCR interactions with self MHC molecules, and
the level of CD8+ T cell loss might be determined, again,
by environmental factors. Our data suggest when CD8+ T
cell loss occurred, it was predominantly seen in the anti-
gen-inexperienced CD44-  pool, which could include
alloantigen-specific naïve T cells. The first-stage treatment
impacts the CD4+ subset also, as there is a small but signif-
icant increase in the percentage of CD4+ cells expressing
memory and activation markers, such as CD44 and CD25.
Taken together, our results indicate there are systematic
variables surmounted reliably by the 2-stage protocol,
which appears to ensure donor stem cell engraftment in
susceptible strains.
The use of co-stimulation blockade with a CD40L mAb
alone has been reported as effective in inducing BM
engraftment, without the need for myeloblative condi-
tioning, although this required a dose of BM one order of
magnitude greater than in our present study [11,12].
Seung and collaborators have reported that BM engraft-
ment (5×107 donor cells) can be facilitated, in the absence
of myelosuppression, by prior infusion of DST under the
cover of anti-CD40L mAbs, or co-administration of
Table 1: T cell sub-populations in mAb treated mice. FACS analysis of splenocytes collected from untreated and antibody-treated 
CBA mice (1 mg YTS177 and 1 mg YTS105 ip given on days -28, -26 and -24 relative to data collection on day 0). 'Total splenocytes' 
refers to all cells in the lymphocyte forward- and side-scatter gate. NS (not significant) p > 0.05; (**) p < 0.001.
Cell phenotype Untreated, n = 6(mean +/- 
SD)%
AntiCD4 + antiCD8 treated, n 
6 (mean +/- SD)%
p value
(CD3+CD8+/total splenocytes) 20.8 +/- 2.6 1.8 +/- 0.6 **
# (CD44+ /CD8+) 6.9 +/- 0.8 36.7 +/- 6.4 **
(CD3+CD4+ /total splenocytes) 32.0 +/- 6.2 37.8 +/- 6.2 NS
# (CD25+ /CD4+) 11.1 +/- 0.7 13.8 +/- 1.0 **
# (CD44+ /CD4+) 8.1 +/- 1.0 14.4 +/- 1.6 **
# Only gated CD3+ cells were taken into account for these calculationsBMC Immunology 2006, 7:9 http://www.biomedcentral.com/1471-2172/7/9
Page 6 of 8
(page number not for citation purposes)
CD40L and CD122 antibodies in the absence of DST [13].
Furthermore, anti-CD40L mAbs have been also shown
useful in enabling the engraftment of clinically attainable
doses of bone marrow with reduced intensity condition-
ing regimes, even in resistant strains such as B6 mice [7-9].
Detailed mechanistic studies have identified a potent
effect of CD40L antibodies on host T cells when alloge-
neic single cell suspensions are delivered intravenously
(donor specific transfusion or bone marrow transplant).
The propensity of host T cells, which recognize the alloan-
tigens, to die under these circumstances is well described
[24,25]. We report that anti-CD40L was an essential com-
ponent of the treatment protocol at the time of transplan-
tation to allow MHC-mismatched bone marrow to
engraft. Further work has demonstrated that an aglycosyl
CD40L mAb with impaired binding to complement and
Fc receptors efficiently enabled engraftment in this proto-
col (Daley et al, manuscript in preparation).
BM engraftment in congenic mice Figure 4
BM engraftment in congenic mice. A dose of 2×107 T 
cell depleted bone marrow cells from B6.CD45.1 mice was 
transplanted into CBA or congenic B6 mice treated with 
mAbs as described in figure 1. (A) One group of B6 mice was 
transplanted in the absence of any mAb treatment, and a 
group of CBA and B6 mice not subjected to BMT was used 
as a negative control. Hematopoietic chimerism was deter-
mined by quantification of peripheral blood mononuclear 
cells 120 days following BMT by flow cytometry. The results 
from two independent experiments are represented. The dif-
ference between the groups treated with mAb and any other 
group is statistically significant (p < 0.001). The difference 
between CBA and B6 recipients of B6.CD45.1 BM under the 
cover of mAbs is also significant in both experiments (p = 
0.04 and p = 0.0006). (B) B6 mice were treated with 1 mg of 
the mAb PK136 administered 5 days prior to transplantation 
of B6.CD45.1 BM, to deplete their NK1.1 cells, while 
another group was treated with the control mAb YCATE55. 
Additional animals were subjected to the treatment 
described in Figure 1. NK cell depletion failed to achieve chi-
merism (p < 0.001).
0
2
4
6
%
 
o
f
 
d
o
n
o
r
 
c
e
l
l
s
0
2
4
6
8
A
B
%
 
o
f
 
d
o
n
o
r
 
c
e
l
l
s
0
1
2
CBA or B6 hosts, B6.CD45.1 donors
1
st stage treatment
(CD4/8/40L) 
2x10
7 2x10
7 2x10
7
2
nd stage treatment
(CD4/8/40L) 
Bone marrow dose
+
+ - +
Host CBA CBA B6 B6 B6
--
--
-- + -
B6 hosts, B6.CD45.1 donors
1
st stage treatment
(CD4/8/40L)  + - -- -
2x10
7 2x10
7 2x10
7
2
nd stage treatment
(CD4/8/40L) 
Bone marrow dose -
-- +
2x10
7
- -
Day -5 treatment --
Anti-
NK1.1
Control
mAb -
MAb requirements at the time of BMT (second-stagetreat- ment) Figure 3
MAb requirements at the time of BMT (second-
stagetreatment). CBA mice were treated with non-
depleting CD4 and CD8 mAbs alone 4 weeks before trans-
plantation of 2 × 107 T cell depleted B10 BM. At the time of 
BMT the mice were treated with CD4 and CD8 mAb alone, 
or combined with CD40L mAb. Chimerism was only 
detected in the mice treated with both co-receptor and co-
stimulation blockade at the time of BMT. Data is representa-
tive of 2 independent experiments.
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Conclusion
Previous studies showed that, in the absence of further
conditioning, targeting either the T cell co-receptors [26]
or the CD40L molecule [13]failed to enable BM engraft-
ment if the mismatch was across both minor and major
histocompatibility barriers. Our combined targeting of
the CD4 and CD8 co-receptors and the CD40L molecule
in a 2-stage protocol seems truly synergistic. Similar pro-
tocols offer an alternative to co-stimulation blockade
alone in enabling the induction of mixed chimerism as
part of a non-myeloablative protocol, or by allowing the
reduction of the cytoreductive component, for treatment
of non-malignant diseases, as well as for malignant dis-
eases prior to the use of donor lymphocyte infusions to
eradicate the tumour.
Methods
Mice
CBA/Ca (CBA, H-2k), BALB/c (H-2d), C57BL/10 (B10, H-
2b), C57BL/6 (B6, H-2b) and B6.SJL.CD45 (B6.CD45.1,
H-2b) mice were bred and maintained in specific patho-
gen free (SPF) facilities at the Sir William Dunn School of
Pathology (Oxford, UK). The animals used in the experi-
ments were sex-matched and between 8 and 10 weeks of
age. Procedures were conducted in accordance with the
Home Office Animals (Scientific Procedures) Act of 1986.
Bone marrow transplantation
BM donors were depleted of T cells with an i.p. injection
of 1 mg of the anti-CD8 mAbs YTS156 and YTS169, and
the anti-CD4 mAbs YTS191 and YTA3.1 five days prior to
BM collection [27]. BM was collected by flushing the
femurs and tibias with RPMI medium. The cells were
counted, resuspended in PBS and injected intravenously
into recipient mice.
Skin grafting
Mice were anaesthetised with a mixture of 1 mg/ml Xyla-
zine (Rompun®, Bayer) and 10 mg/ml Ketamine (Ketaset®,
Fort Dodge). 0.2 ml per 20 g of body weight was injected
i.p. Skin grafting was performed as described elsewhere
[28]. Briefly, skin grafting was conducted by grafting full
thickness tail-skin (1 × 1 cm) on the lateral flank. Grafts
were observed on alternate days after the removal of the
bandage at day 7 and considered rejected when no viable
donor skin was present.
Treatment with mAbs
BMT were performed under the cover of 1 mg YTS177.9, 1
mg YTS105.18 and 1 mg MR1 [29] as described in the text
[15]. All mAbs were produced in our laboratory by culture
in hollow fibre bioreactors, purified from culture superna-
tants by 50% ammonium sulphate precipitation, dialysed
against PBS, and the purity checked by native and SDS gel
electrophoresis (PhastGel, Pharmacia, St. Albans, UK).
Flow cytometry
Hematopoietic chimerism was quantified by staining
peripheral blood with mAbs specific for H-2Db, H-2Kk
and H-2Kd (all from BD Biosciences). To distinguish cells
from the congenic strains we used mAbs specific for
CD45.1 and CD45.2 (BD Biosciences). To study the effect
of first-stage antibody treatment only, splenocytes were
subjected to osmotic lysis of red blood cells before stain-
ing with mAbs specific for CD3, CD4, CD8, CD25 and
CD44 (all from BD Biosciences). Cells were analysed with
a FACScalibur (BD Biosciences) and CellQuest software
(BD Biosciences).
Statistical analysis
Statistical analysis of graft survival was made by the log
rank method. P values in Table 1 were calculated by the
student's T test (unpaired, 2-tailed).
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